Summary:
Labcorp has expanded its precision oncology portfolio with new tests for solid tumors and blood cancers, along with enhanced biopharma solutions to support clinical trials and diagnostic development.
Takeaways:
- New diagnostics aim to improve access and identify patients for targeted cancer therapies.
- Enhanced biopharma solutions are designed to accelerate oncology clinical trials.
- Labcorp emphasizes its role as a trusted partner across all stages of cancer care.
Labcorp, a global provider of innovative and comprehensive laboratory services, has announced the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and hematologic malignancies and enhanced biopharma solutions designed to accelerate clinical trials and companion diagnostic development.
“Labcorp is committed to serving as the trusted partner for advanced testing at every stage of cancer care,” says Shakti Ramkissoon, MD, PhD, vice president and medical lead for oncology at Labcorp. “Our expanded portfolio and integrated solutions provide our partners with the tools and insights they need to accelerate development programs and drive meaningful improvements in patient outcomes.”
Diagnostics: New Solutions for Solid Tumor and Hematologic Malignancies
To improve patient access to testing and identify those who may be eligible for targeted therapies, Labcorp is announcing:
- Availability of new NGS panels for myeloid, lymphoid and pan-heme indications: These new panels offer broader genomic coverage and more clinically actionable insights for patients with hematologic malignancies, helping oncologists and pathologists navigate complex diagnoses and guide treatment decisions with greater speed and clarity.
- The launch of a Rapid AML Panel, enhancing Labcorp’s comprehensive test menu for acute myeloid leukemia: This panel will enable providers to make more timely, informed treatment decisions.
- Expansion of capabilities to OmniSeq INSIGHT: Labcorp’s pan-solid tumor profiling test will soon include homologous recombination deficiency (HRD) testing. The addition of HRD testing will help identify patients with ovarian cancer who are most likely to benefit from targeted therapies such as PARP inhibitors or who may be eligible for clinical trials.
- Expanded FDA-approved companion diagnostics: Additions include the categorization of HER2-low and HER2-ultralow subtypes in the HER2 IHC test for patients with breast cancer and the VENTANA MET (SP44) RxDx Assay for patients with non-squamous non-small cell lung cancer.
- Enabling digital pathology advancements for anatomic pathology with further updates scheduled for 2025.
Biopharma Laboratory Services: Accelerating Clinical Trials and Companion Diagnostic Development
To support global trial consistency and enhance collaboration with the company’s biopharma customers, Labcorp is also announcing:
- Global expansion of Labcorp Plasma Focus: Labcorp will now offer Labcorp Plasma Focus, a solid tumor liquid biopsy test, through its Geneva, Switzerland and Shanghai, China sites. Labcorp Plasma Focus complements the recent global expansion of Labcorp Tissue Complete, a tissue-based comprehensive genomic profiling assay of over 500 genes for pan-solid tumors. Together, the global availability of these assays enables consistent, high-quality testing across regions, reducing variability in results and streamlining workflows for biopharma partners.
- Enhanced digital pathology platform for clinical trials: Labcorp has launched an enhanced digital pathology platform across its global central labs. Utilizing Leica Biosystems Aperio GT450 scanners and Proscia’s Concentriq LS image management system, the platform offers scalable, file-agnostic infrastructure to support scanning, archival and companion diagnostic development. It enables real-time global peer review and delivers more accurate, actionable insights with the ability to integrate high-volume image analysis and leverage AI-driven interpretation.
Featured Image: Catalin Iliescu | Dreamstime.com
